Topical composition moisturiser for relief of dry skin & itching symptoms associated with psoriasis
A synergistic topical composition for psoriasis addresses skin irritation and side effects of existing treatments by combining emollients and anti-inflammatory agents, enhancing skin hydration and absorption, thus improving psoriasis symptoms and quality of life.
Patent Information
- Application Number
- PCT/IN2026/050046
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-01-12
- Publication Date
- 2026-11-12
AI Technical Summary
Current psoriasis treatments, including topical corticosteroids and systemic medications, often cause skin irritation, thinning, or serious side effects, and lack a permanent cure, complicating long-term management due to individual variability and relapses.
A topical composition comprising emollients, occlusive agents, humectants, emulsifying agents, antioxidants, skin barrier restorers, chelating agents, viscosity builders, keratolytic agents, anti-inflammatory agents, and anti-itching agents, which synergistically work to relieve dry skin and itching symptoms in psoriasis without causing irritation or serious side effects.
The composition effectively reduces dryness, scaling, and itching, improves skin hydration, and enhances the absorption of active ingredients, leading to improved skin health and quality of life for psoriasis patients with minimal side effects.
Smart Images

Figure IMGF000016_0001_TABLE 
Figure IMGF000017_0001_TABLE 
Figure IMGF000018_0001_TABLE
Abstract
Description
TITLE OF THE INVENTION:TOPICAL COMPOSITION MOISTURISER FOR RELIEF OF DRY SKIN & ITCHING SYMPTOMS ASSOCIATED WITH PSORIASISCROSS-REFERENCE TO RELATED APPLICATIONS AND PRIORITY The present application claims priority from Indian Patent Application number 202521044448 filed on May 7, 2025, incorporated herein by a reference.FIELD OF THE INVENTION
[0001] The topical composition of Moisturizer for the relief of dry skin & itching symptoms associated with Psoriasis is disclosed in present invention. The composition comprises combination of ingredients that exhibits synergistic effects for the relief of dry skin symptoms like scaling, redness, itching, irritation & flacking associated with psoriasis. The process for preparation of topical composition is also provided herein.BACKGROUND OF THE INVENTION
[0002] Psoriasis is a chronic autoimmune skin disorder that causes the rapid buildup of skin cells, leading to scaling, inflammation, redness, and itching. The most common type is plaque psoriasis, which appears as raised, red patches covered with a silvery-white buildup of dead skin cells, typically on the scalp, elbows, knees, and lower back. Although the exact cause of psoriasis is not fully understood, it is believed to be triggered by an overactive immune system that mistakenly attacks healthy skin cells. Genetic predisposition plays a significant role, as the condition often runs in families. Environmental factors such as infections, stress, certain medications, smoking, and cold weather can also trigger or worsen flare-ups. While psoriasis is not contagious, it can significantly impact a person’s quality of life due to its visible symptoms and associated discomfort.
[0003] The treatment of psoriasis aims to control symptoms, reduce inflammation, and slow the rapid growth of skin cells. It varies based on the severity, type, and extent of the disease. Mild to moderate cases are often managed with topical treatments such as corticosteroids, vitamin D analogues, coal tar, and moisturizers. For moderate to severe psoriasis, phototherapy (light therapy) may be recommended, using natural or artificial ultraviolet light to reduce symptoms. Systemic treatments, including oral or injectable medications like methotrexate, cyclosporine, andbiologies, are used when topical therapies are ineffective. Biologic drugs, which target specific parts of the immune system, have revolutionized psoriasis treatment, offering improved outcomes for patients with severe or resistant disease. Lifestyle changes, stress management, and avoiding known triggers like smoking or certain medications also play a key role in managing the condition effectively. Regular follow-ups and a personalized treatment plan are essential for long-term control.
[0004] Topical treatment is often the first line of therapy for mild to moderate psoriasis and involves applying medication directly to the affected skin to reduce inflammation, scaling, and itching. Common topical treatments include corticosteroids, which help reduce inflammation and slow skin cell turnover, and vitamin D analogues like calcipotriol, which also regulate skin cell growth. Other options include coal tar, salicylic acid, and topical retinoids, which help in softening and removing scales. Moisturizers and emollients are also essential to maintain skin hydration and enhance the effectiveness of medicated treatments. These therapies can be used alone or in combination, depending on the severity and location of the lesions. While topical treatments are generally safe, prolonged use — especially of potent corticosteroids — should be monitored to avoid side effects such as skin thinning or irritation.
[0005] Numerous topical compositions are disclosed in the state of the art for the treatment of psoriasis.
[0006] US2019054062 discloses compositions comprise therapeutically effective amounts of salicylic acid, zinc oxide, bisabolol, at least one pharmaceutically acceptable carrier selected from the group comprising white petrolatum, lanolin, propylene glycol, and combinations thereof, herbal oils selected from the group comprising Salvia Hispanica seed oil, evening primrose oil, grape seed oil, Nigella seed oil, Silybum Marianum oil, Prunus Amygdalus Dulcis (sweet almond) oil, borage oil, Lavendula Angustifolia (lavender) oil, Cannabis sativa seed oil and mixtures thereof and other pharmaceutically acceptable ingredients. Unlike many topical compositions for the treatment of these skin afflictions, the compositions of the instant invention do not contain steroids (like cortisone) or coal tar.
[0007] PH12013500783 discloses nanoemulsions comprising nano size droplets of one or more anti -psoriasis agents, e.g. clobetasol and / or salicylic acid. These compositions exhibit greaterpermeability, and improved bioavailability. The invention also relates to processes for the preparation of such compositions.
[0008] IN202311054541 discloses topical formulation comprises active ingredients 14% to 18% giloy, 14% to 18% nagarmotha, 4% to 6% neem oil, 25% to 29% aloe vera, 4% to 6% babchi, 4% to 6% morninga, 4% to 6% kalonji 7% to 9% nariyal tel, 4% to 6% mentha and 4% to 6% chamomile, 2% - 4 % garlic, preservative, stabilizer and additives and formulate in gel form.
[0009] IN201611033442 discloses extracts of 6 herbs in coconut oil viz. Wrightia tinctoria (fresh leaves), Cynodon dactylon (fresh leaves) Psoralea corylifolia (seeds), Nigella sativa (seeds), Chrysopogon zizanioides (roots) and Barbadensis miller ((leaf flesh) in specific ratios w / w.52:23:10:5:5:5 respectively in coconut oil. For use, the oil is applied on the affected skin for 15 -30 minutes and 2 - 3 times a day.
[0010] Despite advancements in therapy, existing antipsoriasis treatments come with several limitations and challenges. Topical treatments, while effective for mild cases, often require frequent application and may cause skin irritation or thinning with long-term use, especially corticosteroids. Phototherapy, though beneficial, is time-consuming, requires regular clinic visits, and carries a risk of premature skin aging and increased skin cancer risk with prolonged use. Systemic medications like methotrexate and cyclosporine can have serious side effects, including liver, kidney, and immune system toxicity, making long-term use risky. Biologic therapies, though highly effective for moderate to severe psoriasis, are expensive, may not be accessible to all patients, and carry a risk of infections due to immune suppression. Additionally, no current treatment offers a permanent cure, and patients often experience relapses, making long-term management challenging. Variability in individual response and the need for personalized treatment also complicate consistent therapeutic outcomes.
[0011] Present invention provides the topical composition for relief of dry skin symptoms associated with psoriasis providing effective treatment without skin irritation and any serious side effects. Formulation of a present composition for topical administration for the relief of dry skin symptoms associated with psoriasis that not only has therapeutic effects as an anti-inflammatory and suchlike, but is also effective in terms of the visual and social aspect of the disorder, improving its symptoms and increasing the quality of life of the patient who is affected by it.SUMMARY OF THE INVENTION
[0012] This summary is provided to introduce a selection of concepts in a simplified form that is further described below in the detailed description section. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
[0013] According to the teachings of the present invention there is provided the composition for topical moisturizer application for the relief of dry skin symptoms associated with psoriasis.
[0014] In another aspect, the present invention provides a composition that nurtures and heals the dry skin & itching using synergistic composition.
[0015] In another aspect the present invention provides topical composition comprising multiple components that works synergistically for providing relief from dry skin & itching in Psoriasis.
[0016] In another aspect, the present invention provides the topical composition comprising multiple components selected from various categories comprising but not limiting to emollient, occlusive, humectant, emulsifying agent, antioxidant, moisturizer, skin barrier restoring agent, chelating agent, viscosity builder, skin improver, keratolytic agent, exfoliating agent, antiinflammatory & anti-itching, agents that creates a protective barrier that reduces water loss and protects skin from irritants, dead skin cell exfoliating agent, anti-itch, and one or more cosmeceutically acceptable excipients.
[0017] In another aspect, the present invention provides the process for preparation of spreadable composition for topical application to provide relief from dry skin & itching symptoms associated with psoriasis.
[0018] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments.BRIEF DESCRIPTION OF DRAWINGS:Figure 01: Changes in mean PSI score over study durationFigure 02: Changes in mean skin hydration (MMSC readings) over study durationFigure 03: Changes in mean TEWL (VapoMeter readings) over study durationFigure 04: % of participants reporting top 2 scores (agree+ Strongly agree) for various parametersFigure 05: Changes in mean score of itching based on participant feedbackFigure 06: % of participants reporting they were embarrassed or self-conscious because of their skinFigure 07: % of participants reporting that their skin affected any social or leisure activities Figure 08: % of participants reporting that their skin been a problem at work or studying DETAILED DESCRIPTION OF THE INVENTION
[0019] The present invention provides the topical composition characterized by high suitability for application for relief of dry skin and itching symptoms associated with Psoriasis.
[0020] Aspects of the present invention are best understood by reference to the description set forth herein. All the aspects described herein will be better appreciated and understood when considered in conjunction with the following descriptions. It should be understood, however, that the following descriptions, while indicating preferred aspects and numerous specific details thereof, are given by way of example only and should not be treated as limitations. Changes and modifications may be made within the scope herein without departing from the spirit and scope thereof, and the present invention herein includes all such modifications.
[0021] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0022] Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0023] In some embodiments, numbers have been used for quantifying weights, percentages, ratios, and so forth, to describe and claim certain embodiments of the invention and are to be understood as being modified in some instances by the term “about.” Accordingly, in someembodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0024] Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing.
[0025] As used in the description herein and throughout the claims that follow, the meaning of “a,” “an,” and “the” includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise.
[0026] Unless the context requires otherwise, throughout the specification which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense that is as “including, but not limited to.”
[0027] The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.
[0028] The headings and abstract of the invention provided herein are for convenience only and do not interpret the scope or meaning of the embodiments.
[0029] The term, "therapeutically effective amount" as used herein refers to an amount of a formulation or component, effective in producing the desired therapeutic response in a particular patient (subject) suffering from a disease or disorder.
[0030] As used herein the term "topical application" describes application onto a biological surface, e.g., an affected skin or membrane. Hence, the phrase "a composition for topical application" describes a composition that is applied, preferably by spreading, on, for example, skin, eye, ear, scalp, hair or membrane of a subject.
[0031] As used herein, the term "process" and the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
[0032] In one embodiment, the present invention provides the topical composition for the relief of dry skin & itching symptoms associated with psoriasis.
[0033] In another embodiment, the present invention provides the topical composition for the relief of dry skin & itching symptoms associated with psoriasis, wherein the said composition comprises multiple ingredients that synergistically provides effectiveness for management of dry skin & itching symptoms associated with psoriasis.
[0034] In yet another embodiment, the present invention provides the topical composition for relief of dry skin & itching associated symptoms in psoriasis comprising emollient, occlusive agent, emulsifying agent, antioxidant, moisturizer, skin barrier restoring agent, chelating agent, viscosity builder, humectant, skin improver, keratolytic agent, exfoliating agent, anti-inflammatory & antiitching, agents that creates a protective barrier that reduces water loss and protects skin from irritants, dead skin cell exfoliating agent, anti-itch, and one or more cosmeceutically acceptable excipients.
[0035] Emollients supports by maintaining skin hydration, reduce scaling, and improve overall skin barrier function. Although they do not directly treat the underlying inflammation, emollients soften the thickened psoriatic plaques, making the skin more pliable and enhancing the absorption of active topical medications such as corticosteroids or vitamin D analogues. Regular use of emollients helps relieve dryness, itching, and irritation, which can significantly improve patient comfort and adherence to treatment. They are especially beneficial during flare-ups and in maintaining remission, and because they are generally safe and free from serious side effects,emollients can be used frequently and in combination with other therapies to support long-term skin health in individuals with psoriasis.
[0036] Occlusive agents enhances the effectiveness of topical medications and improve skin hydration. These agents work by forming a protective barrier over the skin, which helps to trap moisture, soften scales, and increase the absorption of active ingredients such as corticosteroids or vitamin D analogues. Common occlusive materials include petroleum jelly, Dimethicon, plastic wrap, or specially designed occlusive dressings. When used in combination with topical treatments, occlusion can significantly improve drug penetration, reduce inflammation more effectively, and accelerate healing of psoriatic lesions. However, care must be taken to avoid excessive occlusion, which can lead to skin maceration, irritation, or increased risk of infection. Despite these precautions, occlusive therapy remains a valuable adjunct in managing localized, thick, or resistant plaques of psoriasis.
[0037] Humectants helps to maintain skin hydration and reduce dryness, scaling, and move this after occlusives itching. These substances, such as glycerin, urea, and hyaluronic acid, work by attracting and retaining moisture from the environment or deeper layers of the skin into the outermost layer. In psoriasis, the skin barrier is often compromised, leading to excessive water loss and irritation. By improving skin hydration, humectants enhance the skin’s protective function and can make it more receptive to other topical medications. When used in combination with emollients and medicated creams, humectants help soften psoriatic plaques, improve comfort, and reduce the frequency of flare-ups. Although they do not directly treat the underlying immune dysfunction, humectants are valuable in long-term skincare routines to manage symptoms and support overall skin health in psoriasis patients.
[0038] Emulsifying agents enhances the delivery and effectiveness of active ingredients. These agents help form stable emulsions, allowing oil- and water-based components to mix uniformly, resulting in creams or lotions with improved texture, spreadability, and skin absorption. In psoriasis treatment, emulsifying agents facilitate the even distribution of therapeutic compounds — such as corticosteroids, vitamin D analogues, or moisturizers — across the affected skin, promoting better hydration and drug penetration into the thickened, scaly plaques. They also help maintain skin barrier function by retaining moisture and reducing transepidermal water loss, which is crucial in managing the dryness and irritation associated with psoriasis. The use of emulsifying agentsthus not only improves the efficacy and user experience of topical treatments but also contributes to overall skin comfort and treatment adherence.
[0039] Antioxidants neutralizes oxidative stress, which plays a key role in the pathogenesis of the disease. Psoriasis is associated with increased production of reactive oxygen species (ROS) that contribute to inflammation, keratinocyte hyperproliferation, and immune system dysregulation. Antioxidants such as vitamins A, C, and E, selenium, polyphenols, and plant-based compounds like curcumin and resveratrol help reduce oxidative damage and modulate inflammatory pathways. These compounds can be used as dietary supplements or incorporated into topical formulations to support conventional treatments. By reducing oxidative stress, antioxidants may help improve skin health, decrease flare-ups, and enhance the effectiveness of other therapies, offering a more holistic approach to managing psoriasis with fewer side effects.
[0040] Moisturizers soothe the skin, reduce dryness, and minimize scaling and itching. While they do not treat the underlying inflammation, regular use of moisturizers can significantly improve skin barrier function, making the skin more resilient and enhancing the effectiveness of other topical treatments. Thick, fragrance-free emollients, ointments, and creams are generally preferred as they provide longer-lasting hydration and prevent water loss from the skin. Applying moisturizers immediately after bathing can lock in moisture and soften psoriatic plaques, making medicated creams more effective. In addition to reducing discomfort, consistent moisturizing helps prevent flare-ups and contributes to better overall skin health in individuals with psoriasis.
[0041] Skin barrier restoring agents repaires and strengthens the compromised skin barrier, which is a key feature of the psoriasis. In psoriasis, the skin loses its ability to retain moisture and protect against external irritants due to chronic inflammation and rapid cell turnover. Barrier-restoring agents, such as ceramides, fatty acids, and cholesterol-based moisturizers, help replenish essential lipids in the stratum corneum, improving hydration and reducing transepidermal water loss. These agents not only soothe dryness and scaling but also enhance the effectiveness of other topical treatments by improving their penetration and reducing irritation. By restoring the skin’s natural defense system, these formulations can help reduce flare-ups, minimize symptoms, and support overall skin health, making them a valuable adjunct in both monotherapy and combination therapy for psoriasis management.
[0042] Chelating agents binds and removes excess metal ions, such as iron and copper, which are known to contribute to oxidative stress and inflammation in the skin. By reducing the levels of these pro-oxidant metals, chelating agents help minimize the generation of reactive oxygen species (ROS), which play a role in the pathogenesis of psoriasis. Agents like desferrioxamine and EDTA have shown promise in experimental models by reducing inflammatory markers and improving skin lesions. Additionally, chelation therapy may help restore the balance of essential trace elements, further supporting skin health and immune regulation. While still under investigation, the use of chelating agents offers a novel therapeutic approach that targets the oxidative and inflammatory pathways involved in psoriasis, potentially enhancing the effectiveness of conventional treatments.
[0043] Viscosity builders enhances the consistency, spreadability, and skin retention of active ingredients. By increasing the viscosity of the formulation, these agents help ensure prolonged contact of the drug with the skin, improving absorption and therapeutic efficacy. Common viscosity builders include carbomers, cellulose derivatives (like hydroxypropyl methylcellulose), and natural gums, which help stabilize the formulation and prevent it from running off the skin. This is particularly useful in treating psoriasis plaques, where targeted and sustained delivery of corticosteroids, vitamin D analogues, or other active agents is essential. Additionally, a thicker formulation can form a semi-occlusive barrier that helps retain moisture, reduces transepidermal water loss, and soothes the inflamed skin, offering additional symptomatic relief
[0044] Skin improvers enhances skin hydration, reduces scaling, and improves the overall texture and comfort of affected areas. These agents help to restore the skin’s natural barrier, which is often compromised in psoriatic lesions, thereby reducing dryness, itching, and susceptibility to irritation or infection. Regular use of skin improvers can also enhance the penetration and effectiveness of medicated topical treatments, making them more effective. Some advanced formulations include ingredients like ceramides, hyaluronic acid, or natural oils that not only soothe inflammation but also support skin regeneration. While they are not a cure on their own, skin improvers are essential in the daily care regimen for psoriasis, especially for managing symptoms, preventing flare-ups, and improving the patient’s quality of life.
[0045] Keratolytic agents, works by softening and loosening the dead skin cells on the surface, promoting their removal and reducing the appearance of plaques. By enhancing skin shedding,keratolytic agents can help to alleviate itching and discomfort caused by the condition. They are often used in combination with other treatments, such as corticosteroids, to improve the penetration of active ingredients and enhance their effectiveness. While keratolytic agents are generally well-tolerated, they may cause skin irritation or dryness if used excessively, so it is important for patients to follow proper application guidelines and adjust their use based on the severity of their condition.
[0046] Exfoliating agents remove scales and promote the shedding of dead skin cells, which can build up on the surface due to the rapid skin cell turnover associated with the condition. Agents like salicylic acid, coal tar, and urea are commonly used to soften and loosen scales, allowing other treatments to penetrate more effectively. Salicylic acid, a keratolytic agent, breaks down the bonds between dead skin cells, making it easier for them to be removed, while coal tar helps to reduce itching and inflammation. Urea, on the other hand, helps to hydrate and soften the skin, enhancing the overall skin barrier function. While exfoliating agents can significantly improve the appearance of psoriatic lesions, they must be used with caution, as excessive exfoliation can lead to skin irritation or damage, particularly in sensitive areas. When combined with other treatments like corticosteroids or moisturizers, exfoliating agents can enhance the overall effectiveness of psoriasis management.
[0047] Anti-inflammatory reduces the inflammation that drives the rapid skin cell turnover and formation of plaques. Topical corticosteroids are the most commonly used anti-inflammatory agents, as they effectively decrease swelling, redness, and itching. These steroids work by suppressing the immune system’s overactive response, which is responsible for the inflammatory process. Additionally, non-steroidal anti-inflammatory drugs (NSAIDs) in topical forms may help reduce localized discomfort. Vitamin D analogues, such as calcipotriol, also have antiinflammatory properties by modulating immune cell activity and slowing down the production of skin cells. Systemic anti-inflammatory treatments, including biologic agents like TNF-alpha inhibitors and interleukin inhibitors, target specific immune system pathways involved in inflammation, offering significant relief for patients with moderate to severe psoriasis. These treatments help manage flare-ups and improve skin appearance by addressing the underlying inflammatory processes of the condition.
[0048] In yet another embodiment, the present invention provides the topical composition as an atleast one dosage form selected from but not limiting to cream, ointment, gel, lotion, foam, powder, paste, aerosol, patche, balm, spray, mousse, emollient, emulsion, serum, wipe and the like.
[0049] In a preferred embodiment, the present invention provides the topical composition for relief of dry skin & itching symptoms associated with psoriasis, comprising:one or more emollients,one or more occlusive agentone or more emulsifying agent,atleast one moisturising agentatleast one antioxidant,one or more skin barrier restoring agent,atleast one chelating agent,one or more skin improver,atleast one keratolytic agent,one or more humectant,one or more anti-inflammatory,viscosity builder / s,atleast one agent that creates a protective barrier that reduces water loss and protects skin from irritants,one or more exfoliating agent,one or more anti-itch agent,and one or more cosmeceutically acceptable excipients,wherein any ingredient of the said composition can perform one or more functionalities.
[0050] In a preferred embodiment, the present invention provides the topical composition for relief of dry skin & itching symptoms associated with psoriasis, comprising:1-10% of one or more emollients,0.5% to 15% of one or more occlusive agent1% to 10% of one or more emulsifying agent,2% to 25% of atleast one moisturising agent0.05% to 0.5% of atleast one antioxidant,1% to 10% of one or more skin barrier restoring agent,0.01% to 0.2% of atleast one chelating agent,0.01% to 0.5% of one or more skin improver,5% to 25% of atleast one keratolytic agent,2% to 15% of a humectant,10% to 30% of one or more anti-inflammatory,0.1% to 2% of viscosity builder / s,0.5% to 5% of atleast one agent that creates a protective barrier, reduces water loss and protects skin from irritants,01% to 15% of one or more exfoliating agent,01% to 05 % of Dimethicone,0.01% to 0.2% of Ceramide based composition,0.01% to 0.2% of Allantoin,0.5% to 5% of Salicylic Acid,0.01 % to 0.2% of Hyaluronate,0.5% to 10% of Niacinamide,0.1 % to 2% of Aloe Vera Extract,0.1 % to 3% of Glucanolactone,0.1 % to 2% of Bisabolol,0.01 to 0.5% of one or more anti-itch agent,and one or more cosmeceutically acceptable excipients,wherein any ingredient of the said composition can perform one or more functionalities.
[0051] In yet another embodiment, the present invention provides good to excellent spreadability of the topical formulation according to present invention.
[0052] In yet another embodiment, the present invention provide the topical formulation having pH levels of between 5.0 and 6.0 which is suitable for natural skin pH.
[0053] In yet another embodiment, the present invention provides the topical formulation providing fast to moderate absorption of the ingredients through skin within 1-5 minutes.
[0054] In yet another embodiment, the Viscosity levels of topical formulation typically range from 10,000 to 50,000 centipoise (cP).
[0055] In yet another embodiment, the present invention provides the topical formulation with adequate emolliency, occlusivity, greasiness, stickiness, and smoothness.
[0056] In yet another embodiment, the present invention provides the process for preparation of spreadable composition for topical application to provide relief from dry skin & itching symptoms associated with psoriasis.Clinical Trial evaluation of topical composition;
[0057] In yet another embodiment, the topical composition is subjected to study of safety and efficacy of formulation through subject self evaluation, dermatological evaluation for cosmetic acceptability, dermatological evaluation for efficacy, mexametry, and chromametry and the like.
[0058] The present invention is subjected to in-vivo efficacy and safety in terms of reduction of dry skin & itching symptoms associated with psoriasis.
[0059] In yet another embodiment, the present invention was subjected for a monocentric, parallel group, study to evaluate the efficacy of use of a regime combining a topical steroid and Moisturizing Lotion as compared to use of only Topical Steroid in treatment of Psoriasis.
[0060] The endpoints were as follows:Primary Endpoints• Clinical evaluation using PSI (Psoriasis Severity Index) scale (Baseline - without product application, 2 weeks and 4 weeks)• Skin Hydration Measurement of Stratum corneum using MoistureMeter SC (Baseline - without product application, 1 hour after product application, 2 weeks and 4 weeks) • Trans epidermal water loss by VapoMeter (Baseline - without product application, 1 hour after product application, 2 weeks and 4 weeks)• Self-assessment questionnaire for efficacy (2 weeks and 4 weeks)• Self-assessment of reduction in itching (Baseline, 1 hour, 2 weeks and 4 weeks)• Self-assessment in overall improvement in the quality of life (Baseline, 2 weeks and 4 weeks)Secondary Endpoints:• Clinical evaluation for skin tolerance (1 hour, 2 week and 4week).• Self-assessment questionnaire for skin tolerance (1 hour, 2 week and 4week).
[0061] In yet another embodiment, the Clinical evaluation using PSI scores at all time points was conducted by performing 2 discrete, well circumscribed lesions on body approximately of 2*2 cm2area separated from adjacent lesions was tracked through the entire study by the Investigator and graded as follows: The severity of the lesion was estimated by three clinical signs: erythema (redness), induration (thickness) and desquamation (scaling). Severity parameters were measured on a scale of 0 to 4. None (0), mild (1), moderate (2), severe (3) or very severe (4). The sum of all three severity parameters was then calculated.
[0062] In yet another embodiment, the Skin Hydration Measurement of Stratum corneum using MoistureMeter SC is performed. The skin is electrically layered structure. The electrical properties of these layers are related to their water content. The probe, the skin surface and the deeper skin layers form a structure similar to an electrical capacitor. The measured capacitance is proportional to the water content of the surface layer of the skin. The higher the reading, the higher the moisture content.
[0063] In yet another embodiment, trans epidermal water loss is calculated by VapoMeter which is equipped with a closed cylindrical chamber that contains sensors for relative humidity and temperature. There is a linear increase of relative humidity (RH%) in the chamber shortly after placing the device in contact with the skin. The TEWL (Trans Epidermal Water Loss) is calculated from the increase in RH%. Values of ambient RH (%) and temperature (°C) are recorded before skin contact. The chamber is passively ventilated between measurements. Reduction in the VapoMeter readings indicates prevention of water loss from skin.
[0064] In yet another embodiment, a self-assessment questionnaire was administered to participants to understand their perception of efficacy of product.
[0065] In yet another embodiment, a self-assessment questionnaire was administered to capture reduction in itching on a scale as follows (0=None, l=Mild, 2=Moderate, 3=severe).
[0066] In yet another embodiment, a self-assessment questionnaire was administered to participants to understand their perception of overall improvement in the quality of life.
[0067] In yet another embodiment, the clinical evaluation for reactions in skin was done for calculating Safety Variable(s).
[0068] In yet another embodiment, a self-assessment questionnaire was administered to participants to capture skin tolerance.
[0069] The present disclosure is further described in light of the following experiments which are set forth for illustration purpose only and not to be construed for limiting the scope of the disclosure. The following experiments can be scaled up to industrial / commercial scale and the results obtained can be extrapolated to industrial scale.Example No.01: Formulation of Topical Moisturising composition:&&Manufacturing Procedure:1. In main vessel take Phase B, DM water and heat up to 75 de then add Acrylates / C10-30 Alkyl Acrylate Crosspolymer and homogenize for 30 min to obtained lumps free mixture, then add remaining material of phase B & stir for 15 min.2. Add all the materials of phase A in oil vessel and heat up to 75 de with stirring.3. Add Phase A to Phase B at 75 de and homogenize for 20 min with 2000 rpm.4. Take phase C in active vessel and mix well and add into main vessel & homogenize for 30 min.5. Take Phase D and add into main vessel. Mix well for 5 min.6. Take phase E in active vessel and mix well in water at room temp, and add into main vessel and homogenized for 10 min with stirring.7. Take phase F in active vessel and mix well in water at room temp, and add into main vessel and stir for 10 min with stirring,8. Take phase G in active vessel and mix well in water at room temp, and add into main vessel and homogenized for 10 min with stirring,• Then add material of Phase H one by one and stir for 10 min at the time of every addition.Evaluation of finished composition based on clinical study results:a) Clinical evaluation using PSI scores:Table 1: Changes in mean PSI score over study durationBy Wilcoxon Sign Rank Test *Significant NS = Not SignificantBy Mann Whitney U Test (Betn Groups)Interpretation:
[0070] Significant decrease in values indicates significant improvement in lesions of psoriasis • At the end of Week 2, mean PSI score showed a significant decrease of 3.9% with Betnovate cream and significant decrease of 9.0% with Betnovate cream + Moisturizing lotion from baseline. There was significant difference between groups.• At the end of Week 4, mean PSI score showed a significant decrease of 9.6% with Betnovate cream and significant decrease of 26.8% with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream ± Moisturizing lotion than with Betnovate cream.b) Skin Hydration Measurement using MoistureMeter SCTable 2; Changes in mean skin hydration (MMSC readings) over study duration ;By Student ‘f Test *SignificantInterpretation:
[0071] Significant Increase in values indicates significant increase in skin hydration• At the end of 1-hour, mean Skin Hydration showed a significant increase of 89.2% with Betnovate cream and significant increase of 2.13 times with Betnovate cream ± Moisturizing lotion group from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.• At the end of Week 2, mean Skin Hydration showed a significant increase of 59.8% with Betnovate cream and significant increase of 1.07 can we mention value also times with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.• At the end of Week 4, mean Skin Hydration showed a significant increase of 40.7% with Betnovate cream and significant increase of 1.27 times can we mention value also with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.c) Trans epidermal water loss by VapoMeter;Table 3: Changes in mean TEWL (VapoMeter readings) over study durationBy Student ‘t’ Test *SignificantInterpretation:
[0072] Significant decrease in values indicates significant decrease in TEWL• At the end of 1-hour, mean TEWL showed a significant decrease of 6.6% with Betnovate cream and significant decrease of 19.3% with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.• At the end of Week 2, mean TEWL showed a significant decrease of 7.6% with Betnovate cream and significant decrease of 11.9% in Betnovate cream + Moisturizing lotion from baseline. The change was comparable between groups, and the difference was not significant.• At the end of Week 4, mean TEWL showed a significant decrease of 8.8% with Betnovate cream and significant decrease of 14.3% in Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.d) Self-assessment questionnaire for efficacy:
[0073] A self assessment questionnaire was administered to participants. Participants rated the parameters on a scale of 1-5 with 1 -Strongly disagree, 2= Disagree, 3= Neither agree nor disagree, 4= Agree and 5= Strongly agree. The sum of top 2 scores was taken and % of participants reporting top 2 scores for each parameter was calculated and reported.Table 4: Parameter- After using the product skin has become hydratedBy Chi square Test * Significant• At the end of Week 2, 9.4% of participants agreed to strongly agreed that with Betnovate cream skin has become hydrated, which was significantly less as compared to 34.4% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion skin has become hydrated.• At the end of Week 4, 6.3% of participants agreed to strongly agreed that with Betnovate cream skin has become hydrated, which was significantly less as compared to 71.9% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion skin has become hydrated.Table 5: Parameter- After using the product itching has reducedBy Chi square Test *Significant• At the end of Week 2, 31.3% of participants agreed to strongly agreed that with Betnovate cream itching has reduced, which was significantly less as compared to 90.6% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion itching has reduced.• At the end of Week 4, 40.7% of participants agreed to strongly agreed that with Betnovate cream itching has reduced, which was significantly less as compared to, 93.8% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion itching has reduced.Table 6: Parameter- After using the Product scaling has reducedBy Chi square Test * Significant• At the end of Week 2, 18.8% of participants agreed to strongly agreed that with Betnovate cream scaling has reduced, which was significantly less as compared to 53.1% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion scaling has reduced.• At the end of Week 4, 15.6% of the cases among Betnovate cream agree to strongly agree that scaling has reduced, which was significantly less as compared to 87.5% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion scaling has reduced.Table 7: Parameter- Overall, I liked the productBy Chi square Test *Significant• At the end of Week 2, 18.8% of the participants agreed to strongly agreed that overall, they liked the product-Betnovate cream which was significantly less as compared to 78.1% ofthe participants agreed to strongly agreed that overall, they liked Betnovate cream ± Moisturizing lotion.• At the end of Week 4, 25.0% of the participants agreed to strongly agreed that overall, they liked the product-Betnovate cream which was significantly less as compared to 90.6% participants agreed to strongly agreed that overall, they liked Betnovate cream ± Moisturizing lotion.Table 8: % of participants reporting top 2 scores (agree+ Strongly agree) for various parameterse) Self-assessment of reduction in itching:Table 9: Changes in mean score of itching based on participant feedbackBy Wilcoxon Signed-Rank Test * SignificantBy Mann Whitney U Test (Betn Groups)Interpretation;
[0074] Decrease in values indicates decrease in itching• At the end of 1 hour, mean Itching score showed a significant decrease of 68.4% with Betnovate cream and significant decrease of 69.9% with Betnovate cream + Moisturizing lotion from baseline. If compared, the change was comparable between groups, and the difference was not significant.• At the end of Week 2, mean Itching score showed a significant decrease of 36.4% with Betnovate cream and significant decrease of 59.2% in Betnovate cream + Moisturizing lotion group from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.• At the end of Week 4, mean Itching showed a significant decrease of 57.8% with Betnovate cream and significant decrease of 97.1 % with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.f) Self-assessment in overall improvement in the quality of life:Table 10: % of participants reporting Itchy, sore, painful or stinging skinBy Chi Square Test * SignificantInterpretation :
[0078] % of participants experiencing lot of itchy, sore, painful or stinging skin was tracked over study duration. Decrease in % of participants experiencing lot of itchy, sore, painful or stinging skin indicates improvement.• At baseline, 59.4% of the participants reported experiencing a lot itchy, sore, painful or stinging skin.• After 2 weeks of application, 25.0% of the participants reported experiencing a lot of itchy, sore, painful or stinging skin which showed significant decrease from baseline.• After 4 week of application, none of the participants reported experiencing a lot of itchy, sore, painful or stinging skin which showed significant decrease from baseline.Table 11: % of participants reporting they were embarrassed or self-conscious because of their skinBy Chi Square Test *SignificantInterpretation :
[0075] % of participants experiencing lot of embarrassment or self-consciousness because of their skin was tracked over study duration. Decrease in % of participants experiencing lot of embarrassment or self-consciousness because of their skin indicates improvement.• At baseline, 78.1% of the participants reported that they had been a lot embarrassed or self-conscious because of their skin.• After 2 weeks of application, 50.0% of the participants reported that they had been a lot embarrassed or self-conscious because of their skin which showed significant decrease from baseline.• After 4 weeks of application, none of the participants reported that they had been a lot embarrassed or self-conscious because of their skin which showed significant decrease from baseline.Table 12: % of participants reporting that their skin affected any social or leisure activities:By Chi Square Test *SignificantInterpretation:
[0076] % of participants reporting that their skin affected any social or leisure activities was tracked over study duration. Decrease in % of participants reporting that their skin affected any social or leisure activities indicates improvement.• At baseline, 75.0% of participants reported that their skin affected any social or leisure activities a lot.• After 2 weeks of application, 34.4% of the participants reported that their skin affected any social or leisure activities a lot, which showed a significant decrease from baseline.• After 4 weeks of application, none of the participants reported that their skin affected any social or leisure activities a lot, which showed a significant decrease from baseline. Table 13: % of participants reporting that their skin been a problem at work or studyingBy Chi Square Test * SignificantInterpretation :
[0077] % of participants reporting that their skin had been a problem at work or studying a lot was tracked over study duration. Decrease in % of participants reporting that their skin been a problem at work or studying indicates improvement.• At baseline, 75.0% of participants reported that their skin had been a problem at work or studying a lot.• After 2 weeks of application, 21.9% of the participants reported that their skin had been a problem at work or studying, a lot which showed a significant decrease from baseline.• After 4 weeks of application, none of the participants reported that their skin had been a problem at work or studying, a lot which showed a significant decrease from baseline.SECONDARY ENDPOINTSa) Clinical evaluation for tolerance (1 hour, 2-week, 4 week).
[0078] None of the participants had any skin intolerances.b) Self-assessment questionnaire for skin tolerance (1 hour, 2-week, 4 week).
[0079] None of the participants reported any skin intolerances like Pricking, tingling, itching and burning sensation.Adverse Events (AEs)
[0080] There was no adverse event recorded during the study.DISCUSSION AND OVERALL CONCLUSIONS:
[0081] The objective of this study to evaluate the efficacy of use of a regime combining a topical steroid and test product (Moisturizing Lotion) as compared to use of only Topical Steroid in treatment of Psoriasis. The observations from the study are as follows,PRIMARY ENDPOINTSA. PSI score (Baseline, 2-week, 4 week):
[0082] At the end of Week 2, mean PSI score showed a significant decrease of 3.9% with Betnovate cream and significant decrease of 9.0% with Betnovate cream + Moisturizing lotion from baseline. There was no significant difference between groups.
[0083] At the end of Week 4, mean PSI score showed a significant decrease of 9.6% with Betnovate cream and significant decrease of 26.8% with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.Skin Hydration Measurement of Stratum corneum using MoistureMeter SC (Baseline, 1 hour, 2-week, 4 week):• At the end of 1-hour, mean Skin Hydration showed a significant increase of 89.2% with Betnovate cream and significant increase of 2.13 times with Betnovate cream + Moisturizing lotion group from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.• At the end of Week 2, mean Skin Hydration showed a significant increase of 59.8% with Betnovate cream and significant increase of 1.07 times with Betnovate cream +Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.• At the end of Week 4, mean Skin Hydration showed a significant increase of 40.7% with Betnovate cream and significant increase of 1.27 times with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.B. Trans epidermal water loss by VapoMeter (Baseline, 1 hour, 2-week, 4 week):• At the end of 1-hour, mean TEWL showed a significant decrease of 6.6% with Betnovate cream and significant decrease of 19.3% with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.• At the end of Week 2, mean TEWL showed a significant decrease of 7.6% with Betnovate cream and significant decrease of 11.9% in Betnovate cream + Moisturizing lotion from baseline. The change was comparable between groups, and the difference was not significant.• At the end of Week 4, mean TEWL showed a significant decrease of 8.8% with Betnovate cream and significant decrease of 14.3% in Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.C. Self-assessment questionnaire for efficacy (2-week, 4 week):• At the end of Week 2, 9.4% of participants agreed to strongly agreed that with Betnovate cream skin has become hydrated, which was significantly less as compared to 34.4% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion skin has become hydrated.• At the end of Week 4, 6.3% of participants agreed to strongly agreed that with Betnovate cream skin has become hydrated, which was significantly less as compared to 71.9% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion skin has become hydrated.• At the end of Week 2, 31.3% of participants agreed to strongly agreed that with Betnovate cream itching has reduced, which was significantly less as compared to 90.6% of theparticipants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion itching has reduced.• At the end of Week 4, 40.7% of participants agreed to strongly agreed that with Betnovate cream itching has reduced, which was significantly less as compared to, 93.8% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion itching has reduced.• At the end of Week 2, 18.8% of participants agreed to strongly agreed that with Betnovate cream scaling has reduced, which was significantly less as compared to 53.1% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion scaling has reduced.• At the end of Week 4, 15.6% of the cases among Betnovate cream agree to strongly agree that scaling has reduced, which was significantly less as compared to 87.5% of the participants who agreed to strongly agreed that with Betnovate cream + Moisturizing lotion scaling has reduced.• At the end of Week 2, 18.8% of the participants agreed to strongly agreed that overall, they liked the product-Betnovate cream which was significantly less as compared to 78.1% of the participants agreed to strongly agreed that overall, they liked Betnovate cream + Moisturizing lotion.• At the end of Week 4, 25.0% of the participants agreed to strongly agreed that overall, they liked the product-Betnovate cream which was significantly less as compared to 90.6% participants agreed to strongly agreed that overall, they liked Betnovate cream + Moisturizing lotion.D. Self-assessment of reduction in itching (Baseline, 1 hour, 2-week, 4 week)• At the end of 1 hour, mean Itching score showed a significant decrease of 68.4% with Betnovate cream and significant decrease of 69.9% with Betnovate cream + Moisturizing lotion from baseline. If compared, the change was comparable between groups, and the difference was not significant.• At the end of Week 2, mean Itching score showed a significant decrease of 36.4% with Betnovate cream and significant decrease of 59.2% in Betnovate cream + Moisturizinglotion group from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.• At the end of Week 4, mean Itching showed a significant decrease of 57.8% with Betnovate cream and significant decrease of 97.1 % with Betnovate cream + Moisturizing lotion from baseline. The change was significantly more with Betnovate cream + Moisturizing lotion than with Betnovate cream.E. Self-assessment in overall improvement in the quality of life (Baseline, 2-week, 4 week) % of participants reporting Itchy, sore, painful or stinging skin:• At baseline, 59.4% of the participants reported experiencing a lot itchy, sore, painful or stinging skin.• After 2 weeks of application, 25.0% of the participants reported experiencing a lot of itchy, sore, painful or stinging skin which showed significant decrease from baseline.• After 4 week of application, none of the participants reported experiencing a lot of itchy, sore, painful or stinging skin which showed significant decrease from baseline.% of participants reporting they were embarrassed or self-conscious because of their skin:• At baseline, 78.1% of the participants reported that they had been a lot embarrassed or self-conscious because of their skin.• After 2 weeks of application, 50.0% of the participants reported that they had been a lot embarrassed or self-conscious because of their skin which showed significant decrease from baseline.• After 4 weeks of application, none of the participants reported that they had been a lot embarrassed or self-conscious because of their skin which showed significant decrease from baseline.% of participants reporting that their skin affected any social or leisure activities:• At baseline, 75.0% of participants reported that their skin affected any social or leisure activities a lot.• After 2 weeks of application, 34.4% of the participants reported that their skin affected any social or leisure activities a lot, which showed a significant decrease from baseline.• After 4 weeks of application, none of the participants reported that their skin affected any social or leisure activities a lot, which showed a significant decrease from baseline.% of participants reporting that their skin been a problem at work or studying :• At baseline, 75.0% of participants reported that their skin had been a problem at work or studying a lot.• After 2 weeks of application, 21.9% of the participants reported that their skin had been a problem at work or studying, a lot which showed a significant decrease from baseline.• After 4 weeks of application, none of the participants reported that their skin had been a problem at work or studying, a lot which showed a significant decrease from baseline.Secondary Endpoints:A. Clinical evaluation for tolerance (1 hour, 2-week, 4 week)
[0084] None of the participants had any skin intolerances.B. Self-assessment questionnaire for skin tolerance (1 hour, 2-week, 4 week)
[0085] None of the participants reported any skin intolerances like Pricking, tingling, itching and burning sensation.CONCLUSION:
[0086] At the end of the study, it was concluded that test regime Betnovate Cream with Moisturizing Lotion was significantly better than only Betnovate Cream with respect to the following parameters:• Reducing Psoriasis severity score,• Increasing skin hydration,• Reducing Transepidermal water loss,• Reducing itching,• More than 90% participants agreed itching had reduced and that they liked the product,• More than 85% participants agreed scaling had reduced and more than 70% agreed that their skin had become hydrated,• Quality of Life improved in significant % of participants using test regime,• The regime was well tolerated.
[0087] The embodiments of the invention shown and discussed herein are merely illustrative of modes of application of the present invention. Reference to details in this discussion is not intended to limit the scope of the claims to these details, or to the figures used to illustrate the invention.
Claims
CLAIMS:
1. A synergistic topical composition for alleviating dry skin and itching associated with psoriasis, comprising:1-10 wt.% of one or more emollients;0.5-15 wt.% of one or more occlusive agents;1-10 wt.% of one or more emulsifying agents;2-25 wt.% of at least one moisturizing agent;0.05-0.5 wt.% of at least one antioxidant;1-10 wt.% of one or more skin barrier restoring agents;0.01-0.2 wt.% of at least one chelating agent;0.01-0.5 wt.% of one or more skin improvers;5-25 wt.% of at least one keratolytic agent;2-15 wt.% of one or more humectants;0.1-10 wt.% of one or more anti-inflammatory agents;0.1-2 wt.% of one or more viscosity builders;0.5-5 wt.% of one or more protective barrier-forming agents configured to reduce transepidermal water loss and protect skin from external irritants;0.1-15 wt.% of one or more exfoliating agents;0.01-5 wt.% of dimethicone;0.01-0.2 wt.% of a ceramide-based composition;0.01-0.2 wt.% of allantoin;0.5-5 wt.% of salicylic acid;0.01-0.2 wt.% of a hyaluronate;0.5-10 wt.% of niacinamide;0.1-2 wt.% of aloe vera extract;0.1-3 wt.% of gluconolactone;0.1 -2 wt. % of bisabolol;0.01-0.5 wt.% of one or more anti-itch agents; andone or more cosmetically acceptable excipients,wherein one or more ingredients perform multiple functional roles, and wherein the composition has:a viscosity in the range of 3,000 to 50,000 centipoise,a pH in the range of 5.0 to 6.0, andan absorption time of 1 to 5 minutes following topical application.
2. The composition according to claim 1, wherein the emollients comprise fatty acids, ceramides, or combinations thereof.
3. The composition according to claim 1, wherein the occlusive agents comprise semi- permeable film-forming agents selected from waxes, silicones, or occlusive polymers 4. The composition according to claim 1, wherein the anti-inflammatory and anti-itch agents comprise at least one non-steroidal compound and at least one naturally derived extract.
5. The composition according to claim 1, wherein the viscosity builders comprise a polymer selected from carbomers, cellulose derivatives, or combinations thereof.
6. A process for preparing the synergistic topical composition according to claim 1, comprising:preparing an oil phase by combining emollients, occlusive agents, and skin barrier restoring agents at a temperature of about 75 °C;preparing an aqueous phase by heating deionized water and incorporating moisturizers, humectants, and viscosity builders to a temperature substantially similar to the oil phase;gradually adding the oil phase to the aqueous phase under high-shear mixing to form a uniform emulsion having a viscosity of 3,000-50,000 centipoise and a pH of 5.0- 6.0; andsubsequently incorporating chelating agents, antioxidants, keratolytic agents, antiinflammatory agents, and anti-itch agents under controlled stirring conditions, wherein the process yields a topical composition that is absorbed within 1 to 5 minutes after application.
